Collins, C., Carducci, M. A., Eisenberger, M. A., Isaacs, J. T., Partin, A. W., Pili, R., . . . Denmeade, S. R. (2007). Preclinical and Clinical Studies with the Multi-Kinase Inhibitor CEP-701 as Treatment for Prostate Cancer Demonstrate the Inadequacy of PSA Response as a Primary Endpoint.
Citação norma ChicagoCollins, Connie, Michael A. Carducci, Mario A. Eisenberger, John T. Isaacs, Alan W. Partin, Roberto Pili, Victoria J. Sinibaldi, Janet S. Walczak, and Samuel R. Denmeade. Preclinical and Clinical Studies With the Multi-Kinase Inhibitor CEP-701 As Treatment for Prostate Cancer Demonstrate the Inadequacy of PSA Response As a Primary Endpoint. 2007.
Citação norma MLACollins, Connie, et al. Preclinical and Clinical Studies With the Multi-Kinase Inhibitor CEP-701 As Treatment for Prostate Cancer Demonstrate the Inadequacy of PSA Response As a Primary Endpoint. 2007.